RCS - Avacta Group PLC - Presentations of pre|CISION® Platform Candidates

AvactaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260317:nRSQ8350Wa&default-theme=true

RNS Number : 8350W  Avacta Group PLC  17 March 2026

 

Avacta Announces Preclinical and Translational Presentations of pre|CISION(®)
Platform Candidates at the 2026 AACR Annual Conference

 

 

LONDON and PHILADELPHIA - March 17, 2026 - Avacta Therapeutics (AIM: AVCT,
"the Company", "Avacta"), a clinical stage biopharmaceutical company
developing pre|CISION(®), a tumor-activated oncology delivery platform,
today announced it will deliver two presentations at the American Association
for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April
2026 to 22 April 2026 in San Diego, California, USA.

 

Details of the two presentations:

 

Title: AVA6103 is a FAP-enabled pre|CISION(®) peptide-drug conjugate
delivering sustained release of exatecan in the tumor microenvironment with
potent antitumor activity

 

Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine
Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen
Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson

 

Poster number and Location: 5846, Section 17, Board 15

Session: Tumor Microenvironment, Multi-specifics, and Immunomodulation

Section: Experimental and Molecular Therapeutics

Timing: Tuesday, 21 April 2026, 2:00-5:00pm PDT

 

 

 

Title: Characterization and translational development of novel pre|CISION(®)
technology compounds delivering complementary dual payloads to the tumor
microenvironment following FAP cleavage

 

Authors: Victoria Juskaite, Tom Clough, Ellen Watts , Alexa Kennedy, Iva
Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Greg Billenness,
Douglas Sammon, Sophie Brown, Curtis Rink , Ruairidh Edwards, Vidicha
Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David
Jones

 

Poster number and Location: 5656, Section 10, Board 26

Session: Antibody-Drug Conjugates and Linker Engineering 4

Section: Experimental and Molecular Therapeutics

Timing: Tuesday 21 April 2026, 2:00-5:00pm PDT

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues.

 

Our innovative pipeline consists of pre|CISION(®) peptide drug conjugates
(PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific
release mechanism, providing unique benefits over traditional antibody drug
conjugates.

 

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQQLFFQXLLBBB



            Copyright 2019 Regulatory News Service, all rights reserved